Texas Emerges as Focus of New Trump Administration Actions to Limit Gender-Affirming Care
-
By
-
Lindsey Dawson
-
May 21, 2026
-
Clinical Scorecard: Texas Becomes Central Point for Recent Trump Administration Efforts to Restrict Gender-Affirming Healthcare
At a Glance
| Category | Detail |
| Condition | Gender-Affirming Care Restrictions |
| Key Mechanisms | Federal enforcement actions, subpoenas, and investigations targeting healthcare providers. |
| Target Population | Youth seeking gender-affirming medical care. |
| Care Setting | Healthcare institutions providing gender-affirming care. |
Key Highlights
- Texas has become a focal point for federal actions limiting gender-affirming care.
- Over 40 healthcare institutions have reduced or ceased providing gender-affirming care since early 2025.
- Federal subpoenas have been issued to multiple healthcare providers, including Rhode Island Hospital and NYU Langone Hospital.
- Legal challenges are ongoing regarding the enforcement of subpoenas and the implications for patient privacy.
- State Attorneys General are pushing back against federal actions to maintain access to care.
Guideline-Based Recommendations
Diagnosis
- Monitor ongoing litigation and policy changes affecting gender-affirming care.
Management
- Healthcare providers should remain informed about federal and state regulations regarding gender-affirming care.
- Develop strategies for legal compliance and patient communication.
Monitoring & Follow-up
- Continuously assess the impact of federal actions on the availability of gender-affirming care.
Risks
- Potential legal repercussions for providers who do not comply with federal subpoenas.
Patient & Prescribing Data
Youth requiring gender-affirming medical interventions.
Providers are facing increased scrutiny and pressure regarding off-label prescribing practices.
Clinical Best Practices
- Ensure compliance with state non-discrimination laws while navigating federal regulations.
- Maintain clear communication with patients regarding potential changes in care availability.
- Implement best practices for managing off-label prescribing under increased scrutiny.
Related Resources & Content